(Reuters) - The U.S. Food and Drug Administration on Monday approved expanded use of Merck & Co Inc's antibiotic to treat hospital-acquired pneumonia in patients 18 years and older.
The approval is based on late-stage trial results of the treatment, Zerbaxa, which showed that Merck's drug was as effective as the antibiotic meropenem.
Hospital-acquired pneumonia occurs in patients at least two-three days after being admitted or in those who are on mechanical breathing machines and have life-threatening lung infections with high mortality rates.
(Reporting by Saumya Sibi Joseph and Manojna Maddipatla in Bengaluru; Editing by Maju Samuel)
This story has not been edited by Firstpost staff and is generated by auto-feed.
Your guide to the latest cricket World Cup stories, analysis, reports, opinions, live updates and scores on https://www.firstpost.com/firstcricket/series/icc-cricket-world-cup-2019.html. Follow us on Twitter and Instagram or like our Facebook page for updates throughout the ongoing event in England and Wales.
Updated Date: Jun 04, 2019 02:06:43 IST